SpecificiT completes seed financing

On Sept. 11, cancer company SpecificiT Pharma Inc. (Montreal, Quebec) said it completed an undisclosed seed financing in late August led by Sanderling Ventures. Accel-Rx Health Sciences Accelerator and founding investor AmorChem also participated.

The company has started a Phase I trial of anti-minor histocompatibility complex donor T-lymphocytes expanded ex vivo in patients with relapsed hematologic malignancies following allogeneic hematopoietic stem cell transplantation...